JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Fate Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

1.64 8.61

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.63

Max

1.6600000000000001

Galvenie mērījumi

By Trading Economics

Ienākumi

3.6M

-34M

Pārdošana

278K

1.9M

Peļņas marža

-1,786.576

Darbinieki

181

EBITDA

979K

-37M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+147.27% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 10. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

70M

178M

Iepriekšējā atvēršanas cena

-6.97

Iepriekšējā slēgšanas cena

1.64

Ziņu noskaņojums

By Acuity

50%

50%

147 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. okt. 18:41 UTC

Peļņas

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025. g. 24. okt. 18:31 UTC

Peļņas

Correction to Procter & Gamble to Focus on Innovation

2025. g. 24. okt. 16:25 UTC

Galvenie tirgus virzītāji

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. g. 24. okt. 21:07 UTC

Peļņas

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. g. 24. okt. 20:58 UTC

Peļņas

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. g. 24. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 20:40 UTC

Peļņas

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. g. 24. okt. 20:24 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:23 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:13 UTC

Peļņas

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 20:07 UTC

Tirgus saruna

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. g. 24. okt. 19:40 UTC

Tirgus saruna

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. g. 24. okt. 19:35 UTC

Tirgus saruna

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. g. 24. okt. 19:33 UTC

Peļņas

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025. g. 24. okt. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025. g. 24. okt. 18:52 UTC

Peļņas

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:41 UTC

Peļņas

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:03 UTC

Peļņas

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025. g. 24. okt. 18:02 UTC

Peļņas

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025. g. 24. okt. 18:00 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025. g. 24. okt. 16:57 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025. g. 24. okt. 16:54 UTC

Tirgus saruna

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025. g. 24. okt. 16:44 UTC

Tirgus saruna
Peļņas

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025. g. 24. okt. 16:39 UTC

Tirgus saruna
Peļņas

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025. g. 24. okt. 16:33 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:23 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 16:07 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Fate Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

147.27% augšup

Prognoze 12 mēnešiem

Vidējais 4.08 USD  147.27%

Augstākais 7 USD

Zemākais 2 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fate Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

3

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.9101 / 1.14Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

147 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat